Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.65 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152932 | 1.00 | HSD11B1 (0.65) | HSD11B1LY96BCHEKMT2AALDH1A1 | |
| SCHEMBL29366984 | 1.00 | HSD11B1 (0.65) | HSD11B1LY96BCHEKMT2AALDH1A1 | |
| SCHEMBL10438847 | 0.87 | ALDH1A1 (0.58) | BCHEKMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL69522 | 0.87 | ALDH1A1 (0.58) | BCHEKMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL11061667 | 0.85 | ALDH1A1 (0.56) | BCHEKMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL4777279 | 0.81 | HSD11B1 (0.59) | HSD11B1LY96BCHEKMT2AALDH1A1 | |
| SCHEMBL29608578 | 0.81 | HSD11B1 (0.59) | HSD11B1LY96BCHEKMT2AALDH1A1 | |
| SCHEMBL4777286 | 0.81 | HSD11B1 (0.59) | HSD11B1LY96BCHEKMT2AALDH1A1 | |
| SCHEMBL18046906 | 0.81 | HSD11B1 (0.59) | HSD11B1LY96BCHEKMT2AKDM4E | |
| SCHEMBL18046903 | 0.81 | HSD11B1 (0.59) | HSD11B1LY96BCHEKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3932914-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190241506-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10266487-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2018-10-18 | — | — | US | disclosed |
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| EP-1833789-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS BV (NL) | 2011-07-06 | — | — | EP | disclosed |
| US-7732621-B2 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP ASSETS B.V. (NL) | 2010-06-08 | — | — | US | disclosed |
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| EP-1833789-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSMIP Assets B.V. (NL) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069799-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS B.V. (NL) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676838-A1 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP Assets B.V. (NL) | 2006-07-05 | — | — | EP | disclosed |
| US-4713486-A | ANTIALLERGENS | BEECHAM GROUP P.L.C. (GB) | 1987-12-15 | — | — | US | disclosed |
| EP-0109225-B1 | ARACHIDONIC ACID ANALOGUES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN MEDICINE | BEECHAM GROUP PLC (GB) | 1985-08-28 | — | — | EP | disclosed |
| EP-0109225-A1 | Arachidonic acid analogues, processes for their preparation and their use in medicine | BEECHAM GROUP PLC (GB) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | HSD11B1 3561/4885LY96 4847/4885BCHE 63/4885 |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
| US-10266487-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
| US-20190241506-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | IDO2, IDO1, KYNU | HSD11B1 772/4885LY96 4011/4885BCHE 506/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | HDAC8, HDAC7, HDAC1 | HSD11B1 422/4885LY96 3504/4885BCHE 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.